Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Operating Room Supply Cost Awareness: A Cross-Sectional Analysis.

Schmidt B, Meng MV, Hampson LA.

Urol Pract. 2019 Mar;6(2):73-78. doi: 10.1016/j.urpr.2018.04.003. Epub 2018 Apr 27.

PMID:
31106254
2.

Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer.

Washington SL 3rd, Neuhaus J, Meng MV, Porten SP.

Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1339-1344. doi: 10.1158/1055-9965.EPI-18-1280. Epub 2019 May 15.

PMID:
31092404
3.

Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer.

Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC.

J Urol. 2019 May 1:101097JU0000000000000297. doi: 10.1097/JU.0000000000000297. [Epub ahead of print]

PMID:
31042108
4.

Editorial: Conversion to negative surgical margin after intraoperative frozen section - (un)necessary effort and relevance in 2019?

Herlemann A, Meng MV.

BJU Int. 2019 May;123(5):744-746. doi: 10.1111/bju.14610. No abstract available.

PMID:
31008557
5.

Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

Balakrishnan AS, Washington SL 3rd, Meng MV, Porten SP.

Clin Genitourin Cancer. 2019 Jun;17(3):e461-e471. doi: 10.1016/j.clgc.2019.01.007. Epub 2019 Jan 19.

PMID:
30799130
6.

Variation in Laparoscopic Nephrectomy Surgical Costs: Opportunities for High Value Care Delivery.

Hampson LA, Odisho AY, Meng MV.

Urol Pract. 2018 Sep;5(5):334-341. doi: 10.1016/j.urpr.2017.09.003.

PMID:
30746428
7.

Development and validation of surgical training tool: cystectomy assessment and surgical evaluation (CASE) for robot-assisted radical cystectomy for men.

Hussein AA, Sexton KJ, May PR, Meng MV, Hosseini A, Eun DD, Daneshmand S, Bochner BH, Peabody JO, Abaza R, Skinner EC, Hautmann RE, Guru KA.

Surg Endosc. 2018 Nov;32(11):4458-4464. doi: 10.1007/s00464-018-6191-3. Epub 2018 Apr 13.

8.

Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.

Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP.

Clin Epigenetics. 2018 Feb 12;10:19. doi: 10.1186/s13148-018-0451-x. eCollection 2018.

9.

Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.

Wallace E, Higuchi R, Satya M, McCann L, Sin MLY, Bridge JA, Wei H, Zhang J, Wong E, Hiar A, Mach KE, Scherr D, Egerdie RB, Ohta S, Sexton WJ, Meng MV, Weizer AZ, Woods M, Jansz GK, Zadra J, Lotan Y, Goldfarb B, Liao JC.

J Urol. 2018 Mar;199(3):655-662. doi: 10.1016/j.juro.2017.09.141. Epub 2017 Oct 20.

PMID:
29061538
10.

The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.

Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP.

Cancer. 2017 Dec 1;123(23):4574-4582. doi: 10.1002/cncr.30918. Epub 2017 Sep 7.

11.

Variation and Predictors of Surgical Case Costs among Urologists.

Hampson LA, Odisho AY, Meng MV, Carroll PR.

Urol Pract. 2017 Jul;4(4):277-284. doi: 10.1016/j.urpr.2016.07.005. Epub 2016 Oct 15.

12.

An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.

Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP.

J Urol. 2017 Aug;198(2):329-334. doi: 10.1016/j.juro.2017.01.103. Epub 2017 Mar 29.

PMID:
28363690
13.

Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes.

Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M 3rd, Carroll PR.

PLoS One. 2016 Oct 6;11(10):e0164558. doi: 10.1371/journal.pone.0164558. eCollection 2016.

14.

A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy.

Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR.

J Urol. 2017 Feb;197(2):369-375. doi: 10.1016/j.juro.2016.08.122. Epub 2016 Sep 28.

PMID:
27693447
15.

Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy.

Leapman MS, Ameli N, Shinohara K, Nguyen HG, Meng MV, Cooperberg MR, Carroll PR.

Clin Genitourin Cancer. 2017 Feb;15(1):93-99. doi: 10.1016/j.clgc.2016.07.011. Epub 2016 Jul 21.

PMID:
27522449
16.

Diet and lifestyle can influence prostate cancer outcomes.

Leapman MS, Clark CJ, Meng MV, Boughey JC.

Bull Am Coll Surg. 2016 Jul;101(7):50-2. No abstract available.

PMID:
28941449
17.

Development of CNS-type Primitive Neuroectodermal Tumor in Metastatic Testicular Mixed Germ Cell Tumor.

Odisho AY, Rabban JT, Meng MV.

Urol Case Rep. 2016 Feb 17;6:7-8. doi: 10.1016/j.eucr.2016.01.003. eCollection 2016 May.

18.

Editorial Comment.

Meng MV.

Urology. 2016 May;91:232-3. doi: 10.1016/j.urology.2015.11.061. No abstract available.

PMID:
27107200
19.

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.

20.

Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison.

Sanford T, Porten S, Meng MV.

PLoS One. 2015 Aug 28;10(8):e0137141. doi: 10.1371/journal.pone.0137141. eCollection 2015.

21.

Editorial Comment.

Meng MV.

J Urol. 2015 Aug;194(2):309. doi: 10.1016/j.juro.2015.02.2957. Epub 2015 May 19. No abstract available.

PMID:
26001977
22.

Concurrent urologic and palliative care after cystectomy for treatment of muscle-invasive bladder cancer.

Rabow MW, Benner C, Shepard N, Meng MV.

Urol Oncol. 2015 Jun;33(6):267.e23-9. doi: 10.1016/j.urolonc.2015.02.012. Epub 2015 Mar 23.

PMID:
25814144
23.

Treating metastatic prostate cancer now and in the future.

Meng MV, Boughey JC.

Bull Am Coll Surg. 2014 Sep;99(9):55-7. No abstract available.

PMID:
25272429
24.

Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.

Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR.

J Urol. 2015 Mar;193(3):807-11. doi: 10.1016/j.juro.2014.09.094. Epub 2014 Sep 28.

25.

The future of quality in urologic oncology: evaluating the horizon of surgical standards.

Hampson LA, Brajtbord JS, Meng MV.

Urol Oncol. 2014 Aug;32(6):735-40. No abstract available.

PMID:
25232559
26.

Editorial comment for Zargar et al.

Meng MV.

J Endourol. 2015 Jan;29(1):102. doi: 10.1089/end.2014.0535. No abstract available.

PMID:
25102379
27.

Prostate cancer screening and risk of litigation: caught between Scylla and Charybdis.

Hsieh MH, Meng MV.

J Urol. 2014 Jun;191(6):1648-9. doi: 10.1016/j.juro.2014.03.085. Epub 2014 Mar 18. No abstract available.

PMID:
24656674
28.

A risk-adjusted definition of biochemical recurrence after radical prostatectomy.

Morgan TM, Meng MV, Cooperberg MR, Cowan JE, Weinberg V, Carroll PR, Lin DW.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):174-9. doi: 10.1038/pcan.2014.5. Epub 2014 Mar 11.

PMID:
24614692
29.

Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes.

Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M 3rd, Carroll PR.

PLoS One. 2014 Mar 3;9(3):e89754. doi: 10.1371/journal.pone.0089754. eCollection 2014. Erratum in: PLoS One. 2016 Oct 6;11(10 ):e0164558.

30.

Antidepressants and testicular cancer.

Friedman GD, Schwalbe J, Achacoso N, Meng MV, Kroenke CH, Habel LA.

Cancer Causes Control. 2014 Feb;25(2):251-8. doi: 10.1007/s10552-013-0327-5. Epub 2013 Nov 26.

31.

The natural history of symptoms and distress in patients and families following cystectomy for treatment of muscle invasive bladder cancer.

Benner C, Greenberg M, Shepard N, Meng MV, Rabow MW.

J Urol. 2014 Apr;191(4):937-42. doi: 10.1016/j.juro.2013.10.101. Epub 2013 Oct 29.

PMID:
24184369
32.

Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.

Cary KC, Cowan JE, Sanford M, Shinohara K, Perez N, Chan JM, Meng MV, Carroll PR.

Eur Urol. 2014 Aug;66(2):337-42. doi: 10.1016/j.eururo.2013.08.060. Epub 2013 Sep 9.

PMID:
24035632
33.

What is the appropriate extent of lymphadenectomy for bladder cancer?

Meng MV, Nelson H.

Bull Am Coll Surg. 2013 Jul;98(7):60-2. No abstract available.

PMID:
24010224
34.

Editorial comment.

Meng MV.

Urology. 2013 Sep;82(3):545-6. doi: 10.1016/j.urology.2013.03.093. No abstract available.

PMID:
23987149
35.

Benign prostate glandular tissue at radical prostatectomy surgical margins.

Odisho AY, Washington SL 3rd, Meng MV, Cowan JE, Simko JP, Carroll PR.

Urology. 2013 Jul;82(1):154-9. doi: 10.1016/j.urology.2012.12.063. Epub 2013 Mar 21.

36.

How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer?

Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR.

BJU Int. 2013 Aug;112(4):E314-20. doi: 10.1111/j.1464-410X.2012.11493.x. Epub 2013 Mar 4.

41.

The role of active surveillance in the management of prostate cancer.

Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M.

J Natl Compr Canc Netw. 2013 Feb 1;11(2):183-7.

PMID:
23411385
42.

Role of active surveillance in the management of localized prostate cancer.

Glass AS, Cooperberg MR, Meng MV, Carroll PR.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):202-6. doi: 10.1093/jncimonographs/lgs032.

43.

The use of mannitol in partial and live donor nephrectomy: an international survey.

Cosentino M, Breda A, Sanguedolce F, Landman J, Stolzenburg JU, Verze P, Rassweiler J, Van Poppel H, Klingler HC, Janetschek G, Celia A, Kim FJ, Thalmann G, Nagele U, Mogorovich A, Bolenz C, Knoll T, Porpiglia F, Alvarez-Maestro M, Francesca F, Deho F, Eggener S, Abbou C, Meng MV, Aron M, Laguna P, Mladenov D, D'Addessi A, Bove P, Schiavina R, De Cobelli O, Merseburger AS, Dalpiaz O, D'Ancona FC, Polascik TJ, Muschter R, Leppert TJ, Villavicencio H.

World J Urol. 2013 Aug;31(4):977-82. doi: 10.1007/s00345-012-1003-1. Epub 2012 Dec 15.

PMID:
23242033
44.

Computed tomography and magnetic resonance imaging of adult renal cell carcinoma associated with Xp11.2 translocation.

Dang TT, Ziv E, Weinstein S, Meng MV, Wang Z, Coakley FV.

J Comput Assist Tomogr. 2012 Nov-Dec;36(6):669-74. doi: 10.1097/RCT.0b013e3182680182.

PMID:
23192203
45.

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.

Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM.

J Urol. 2012 Dec;188(6):2391-7. doi: 10.1016/j.juro.2012.07.097. Epub 2012 Oct 22.

PMID:
23088985
46.

What's new in renal cell carcinoma.

Meng MV, Nelson H.

Bull Am Coll Surg. 2012 Aug;97(8):65-6. No abstract available.

PMID:
22973751
47.

Editorial comment.

Meng MV.

Urology. 2012 Aug;80(2):359; author reply 359-60. doi: 10.1016/j.urology.2012.03.068. No abstract available.

PMID:
22857753
48.

Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses.

Whitson JM, Harris CR, Meng MV.

BJU Int. 2012 Nov;110(10):1438-43; discussion 1443. doi: 10.1111/j.1464-410X.2012.11113.x. Epub 2012 May 28.

49.

Under-grading of <4 cm renal masses on renal biopsy.

Harris CR, Whitson JM, Meng MV.

BJU Int. 2012 Sep;110(6):794-7. doi: 10.1111/j.1464-410X.2012.10944.x. Epub 2012 Mar 9.

50.

Evolving practice patterns for the management of small renal masses in the USA.

Yang G, Villalta JD, Meng MV, Whitson JM.

BJU Int. 2012 Oct;110(8):1156-61. doi: 10.1111/j.1464-410X.2012.10969.x. Epub 2012 Feb 28.

Supplemental Content

Support Center